Table 1 Clinical and laboratory characteristics of vaccinated MM patients with SARS-CoV-2 infection.
From: SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
Pt | Age (yrs) | Sex | Comorbidities | Tipe of MM | Hematologic therapies at the time of infection | Previous therapies for MM | Immunoparesisa | Lympho penia (<1000/ mm3) | Date of diagnosis of SARS-CoV-2 infection | Date of first/second dose of BNT162b2 mRNA vaccine | Days from fully vaccination to SARS-CoV-2 infection | COVID-19 Symptoms | SARS-CoV-2 Variant of Concern | Anti-spike IgGb before infection/days from fully vaccination | Anti-spike IgGb post infection/days from fully vaccination | Anti SARS-CoV-2c IgM/IgG days from infection |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 76 | F | Hypertension Severe obesity Chronic obstructive bronchopathy Chronic renal failure | SMM, IgA λ | No | No | No | No | 03/06/2021 | 21/04/2021 12/05/2021 | 21 | Diarrhea | Alpha (lineage B.1.1.7) | N.A. | 2812/184 | IgM−/IgG− 162 |
2 | 71 | F | Diabetes mellitus Hypothyroidism | MM, IgG k | Radiotherapy | No | Yes | Yes | 09/08/2021 | 22/04/2021 18/05/2021 | 83 | Dry cough | Delta (lineage B.1.617.2) | N.A. | 495/178 | IgM−/IgG− 95 |
3 | 56 | M | Hypertension Glomerulonephritis with C3-deposits Kidney-transplant recipient | SMM, IgG λ | Cyclosporin | No | No | No | 24/08/2021 | 27/03/2021 17/04/2021 | 129 | Fever Pneumonia | Delta (lineage B.1.617.2) | N.A | 592/205 | IgM−/IgG+ 76 |
4 | 70 | M | Hypertension | MM, IgG k | DRd | VAD, sASCT, VTD | No | No | 06/09/2021 | 06/05/2021 12/06/2021 | 86 | No | Delta (lineage B.1.617.2) | N.A. | 682/149 | IgM+/IgG− 63 |
5 | 54 | F | Hypothyroidism | MM, IgG k | Lenalidomide | VTD, dASCT | Yes | Yes | 10/09/2021 | 01/04/2021 23/04/2021 | 140 | Fever | Delta (lineage B.1.617.2) | 828/30 | 26710/199 | IgM−/IgG+ 59 |
